Carboplatin
Metastatic Malignant Neoplasm In The Brain
Explore 101 assets in Metastatic Malignant Neoplasm In The Brain →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07638852CT.gov Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM. | — | Recruiting | — | — | — |
NCT07365410CT.gov Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study | — | Not Yet Recruiting | — | — | — |
NCT06822543CT.gov A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) | — | Recruiting | — | — | — |
NCT06684873CT.gov A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN) | — | Not Yet Recruiting | — | — | — |
NCT06253871CT.gov A Phase 1/1b Study of IAM1363 in HER2 Cancers | — | Recruiting | — | — | — |
NCT05812534CT.gov Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases | — | Unknown | — | — | — |
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT05241873CT.gov (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | — | Terminated | — | — | — |
NCT05012254CT.gov Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases | — | Active Not Recruiting | — | — | — |
NCT04631029CT.gov Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | — | Completed | — | — | — |
Show 3 more trialsShow fewer
NCT04610684CT.gov Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | — | Terminated | — | — | — |
NCT04507217CT.gov Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC | — | Completed | — | — | — |
NCT04211090CT.gov Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Malignant Neoplasm In The Brain
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | Fudan University | P2 | B · 62 |
| Trastuzumab | Iambic Therapeutics, Inc | P4 | BB |
| Icotinib | Betta Pharmaceuticals Co., Ltd. | P3 | BB |
| Trastuzumab Deruxtecan | Baptist Health South Florida | P4 | BB |
| Copper Cu 64-Dota-Trastuzumab | City of Hope Medical Center | P4 | BB |
| Capecitabine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Memantine | NRG Oncology | P3 | BB |
| Regorafenib | Neonc Technologies, Inc. | P2 | BB |
| Gefitinib | Alpha Biopharma (Jiangsu) Co., Ltd. | P3 | B |
+42 more in the Metastatic Malignant Neoplasm In The Brain cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Carboplatin in Metastatic Malignant Neoplasm In The Brain. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carboplatin-metastatic-malignant-neoplasm-in-the-brain
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →